Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.
Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI.
Quandt Z, et al. Among authors: jacob s.
BJC Rep. 2024 Jun 24;2(1):46. doi: 10.1038/s44276-024-00057-7.
BJC Rep. 2024.
PMID: 39516257
Free PMC article.